Simcere Pharmaceutical Gr Stock (OTC: SMHGF)

Latest news for Simcere Pharmaceutical Gr (OTC:SMHGF) Stock

Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases, and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Asia

Biotech

Markets

General

SHJBF

SMHGF

Key Takeaways:


	The drugs Xiannuoxin and Mindewei have been conditionally approved for marketing in China. Despite the positive news, Simcere Pharmaceutical’s stock managed only a muted rise and shares in Junshi Biosciences fell for two straight days


Past the Peak? Covid Drugs Frenzy Cools As Pandemic Eases

SIMCERE PHARM GRP LTD by SIMCERE PHARMACEUTICAL GROUP LTD

Simcere Pharmaceutical Group Ltd

News

IPOs

Park Ha Biological Technology Co Ltd Shares Open For Trade At $4.10 Per Share; IPO Priced At $4.00 Per Share

Investors with a lot of money to spend have taken a bullish stance on Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with QUBT, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 19 uncommon options trades for Quantum Computing.
This isn't normal.
The overall sentiment of these big-money traders is split between 42% bullish and 31%, bearish.
Out of all of the special options we uncovered, 9 are puts, for a total amount of $455,775, and 10 are calls, for a total amount of $688,739.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $12.5 to $25.0 for Quantum Computing over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Quantum Computing options trades today is 2280.4 with a total volume of 9,055.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Quantum Computing's big money trades within a strike price range of $12.5 to $25.0 over the last 30 days.
<h3>Quantum Computing Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735317042_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>QUBT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$4.5</td>
<td>$4.4</td>
<td>$4.5</td>
<td>$20.00</td>
<td>$137.0K</td>
<td>876</td>
<td>308</td>
</tr>
<tr>
<td>QUBT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.7</td>
<td>$3.5</td>
<td>$3.7</td>
<td>$18.00</td>
<td>$111.0K</td>
<td>1.7K</td>
<td>527</td>
</tr>
<tr>
<td>QUBT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/10/25</td>
<td>$3.2</td>
<td>$2.95</td>
<td>$3.2</td>
<td>$18.00</td>
<td>$96.0K</td>
<td>372</td>
<td>489</td>
</tr>
<tr>
<td>QUBT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.6</td>
<td>$5.4</td>
<td>$5.45</td>
<td>$20.00</td>
<td>$92.6K</td>
<td>1.5K</td>
<td>823</td>
</tr>
<tr>
<td>QUBT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.6</td>
<td>$5.5</td>
<td>$5.5</td>
<td>$20.00</td>
<td>$82.6K</td>
<td>1.5K</td>
<td>1.1K</td>
</tr>
</tbody>
</table>

<h3>About Quantum Computing</h3>
Quantum Computing Inc is an American company utilizing non-linear quantum optics (optical devices whose output due to quantum effects is exponentially, not linearly, related to inputs) to deliver quantum products for high-performance computing applications. QCi's products are designed to operate at room temperature and use low power at an affordable cost. The Company's portfolio of core technology and products offer new capabilities in the areas of high-performance computing, artificial intelligence, cyber security as well as remote sensing applications.
In light of the recent options history for Quantum Computing, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Quantum Computing</h3>
<ul>
<li>With a volume of 33,862,378, the price of QUBT is down -4.95% at $18.29. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 94 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Quantum Computing with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

QUBT

Market Whales and Their Recent Bets on QUBT Options

Deep-pocketed investors have adopted a bullish approach towards Barrick Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GOLD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Barrick Gold. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 44% leaning bullish and 33% bearish. Among these notable options, 2 are puts, totaling $95,041, and 7 are calls, amounting to $429,726.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $5.0 and $30.0 for Barrick Gold, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Barrick Gold's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Barrick Gold's whale trades within a strike price range from $5.0 to $30.0 in the last 30 days. 
<h3>Barrick Gold Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735317037_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$1.11</td>
<td>$1.09</td>
<td>$1.1</td>
<td>$20.00</td>
<td>$106.9K</td>
<td>109.2K</td>
<td>1.8K</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.09</td>
<td>$1.07</td>
<td>$1.09</td>
<td>$20.00</td>
<td>$93.4K</td>
<td>109.2K</td>
<td>861</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$0.62</td>
<td>$0.61</td>
<td>$0.61</td>
<td>$30.00</td>
<td>$77.9K</td>
<td>534</td>
<td>1.4K</td>
</tr>
<tr>
<td>GOLD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.89</td>
<td>$1.84</td>
<td>$1.89</td>
<td>$17.00</td>
<td>$66.1K</td>
<td>8.0K</td>
<td>610</td>
</tr>
<tr>
<td>GOLD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$9.5</td>
<td>$9.35</td>
<td>$9.41</td>
<td>$25.00</td>
<td>$52.6K</td>
<td>715</td>
<td>101</td>
</tr>
</tbody>
</table>

<h3>About Barrick Gold</h3>
Based in Toronto, Barrick Gold is one of the world's largest gold miners. In 2023, the firm produced nearly 4.1 million attributable ounces of gold and about 420 million pounds of copper. At year-end 2023, Barrick had about two decades of gold reserves along with significant copper reserves. After buying Randgold in 2019 and combining its Nevada mines in a joint venture with competitor Newmont later that year, it operates mines in 19 countries in the Americas, Africa, the Middle East, and Asia. The company also has growing copper exposure. Its potential Reko Diq project in Pakistan, if developed, could double copper production by the end of the decade.
After a thorough review of the options trading surrounding Barrick Gold, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Barrick Gold Standing Right Now?</h3>
<ul>
<li>With a volume of 3,871,346, the price of GOLD is down -0.22% at $15.71. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 47 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Barrick Gold with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

GOLD

Decoding Barrick Gold's Options Activity: What's the Big Picture?

Whales with a lot of money to spend have taken a noticeably bearish stance on Cleanspark.
Looking at options history for Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) we detected 20 trades.
If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $648,322 and 16, calls, for a total amount of $631,476.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $8.0 and $37.0 for Cleanspark, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Cleanspark options trades today is 13555.59 with a total volume of 18,722.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Cleanspark's big money trades within a strike price range of $8.0 to $37.0 over the last 30 days.
<h3>Cleanspark Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735317032_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$27.75</td>
<td>$27.6</td>
<td>$27.6</td>
<td>$37.00</td>
<td>$480.2K</td>
<td>6.4K</td>
<td align="right">174</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.1</td>
<td>$3.95</td>
<td>$4.15</td>
<td>$10.00</td>
<td>$83.0K</td>
<td>7.1K</td>
<td align="right">203</td>
</tr>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$4.5</td>
<td>$3.4</td>
<td>$4.49</td>
<td>$15.00</td>
<td>$62.4K</td>
<td>7.9K</td>
<td align="right">167</td>
</tr>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$0.88</td>
<td>$0.85</td>
<td>$0.88</td>
<td>$10.00</td>
<td>$59.6K</td>
<td>25.2K</td>
<td align="right">915</td>
</tr>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$1.1</td>
<td>$1.08</td>
<td>$1.09</td>
<td>$10.00</td>
<td>$56.7K</td>
<td>548</td>
<td align="right">554</td>
</tr>
</tbody>
</table>

<h3>About Cleanspark</h3>
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
<h3>Current Position of Cleanspark</h3>
<ul>
<li>Trading volume stands at 10,626,625, with CLSK's price up by 0.19%, positioned at $10.38.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 41 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cleanspark options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

CLSK

Check Out What Whales Are Doing With CLSK

Rising mortgage costs have created an unexpected silver lining for many young professionals priced out of homeownership – driving <a href="https://www.benzinga.com/real-estate/24/03/37613057/occupancy-rate-in-new-yorks-luxury-rental-sector-at-a-30-year-high">demand for luxury rental properties that offer amenities far beyond typical starter homes</a>. A new CBRE study by Forbes revealed a 35% gap between average monthly mortgage payments and apartment rents, sparked by a 75% surge in mortgage costs since 2019.
That affordability gap has transformed rental market dynamics, with upscale apartment developers competing to attract long-term tenants through resort-style amenities. New York&#8217;s The Ellery and Miami&#8217;s 2000 Biscayne are examples of the trend, both reaching 50% occupancy within months of opening.
Don't Miss:
<ul>
<li>During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
</ul>
&#8220;Renters in today&#8217;s luxury market want to be wowed, which inspired us to focus on stunning views, hotel-level amenities and museum-level art,&#8221; Colleen Wenke, president of Taconic Partners, developer of The Ellery, explained to Forbes. The 32-story Manhattan property features private dining rooms with wine fridges, a full-service spa and a rooftop pool with cabanas.
In Miami, 2000 Biscayne caters to similar preferences with a 5,000-square-foot fitness center, wellness spa and outdoor yoga areas overlooking Biscayne Bay. &#8220;Renters increasingly place a premium on health and wellness, productivity, calm and convenience,&#8221; Nicholas Pantuliano, COO of PTM Partners, said.
The trend extends beyond coastal markets. Philadelphia&#8217;s The Noble offers a year-round 75-foot pool, a 17,000-square-foot gym and extensive coworking spaces, reflecting nationwide demand for lifestyle-focused rental communities.
See Also: Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a>
CBRE forecasts that the homeownership premium will decrease but remain significant enough to keep many potential buyers in luxury rentals longer. The shift has prompted developers to emphasize amenities previously associated with high-end condominiums, from wine storage to private treatment rooms.
The appeal stems partly from flexibility – the properties offer upscale living without the maintenance responsibilities or long-term homeownership commitment. For millennials facing an uncertain housing market, luxury rentals provide immediate access to premium lifestyles while keeping future options open.
The evolution in rental housing reflects broader changes in how young professionals view home and community. Rather than settling for modest starter homes in distant suburbs, many opt for <a href="https://www.benzinga.com/real-estate/24/09/41021604/a-surprising-housing-trend-is-sweeping-the-u-s-why-built-to-rent-communities-are-about-to-redefine-t">amenity-rich urban rentals that better align with their current lifestyle</a> preferences and values.
Read Next:
<ul>
<li>It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a></li>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
</ul>

Real Estate

Why Millennials Are Choosing Apartments With Wine Fridges Over Starter Homes

Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) has outperformed the market over the past 15 years by 3.25% on an annualized basis producing an average annual return of 14.91%. Currently, Starbucks has a market capitalization of $103.05 billion. 
Buying $1000 In SBUX: If an investor had bought $1000 of SBUX stock 15 years ago, it would be worth $8,043.82 today based on a price of $90.89 for SBUX at the time of writing.
<h3>Starbucks's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735317009_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

SBUX

Here's How Much $1000 Invested In Starbucks 15 Years Ago Would Be Worth Today

Park Ha Biological Technology Co IPO Indicating $4.00 Per Share On 27,860 Shares

Trading Halt: Halt status updated at 11:25:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

The <a href="https://www.benzinga.com/topic/gold">glitter of gold </a>is losing its luster for two mining giants, Barrick Gold Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) and Newmont Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), as both stocks have hit a <a href="https://www.benzinga.com/topic/death-cross">technical Death Cross</a>—a bearish signal when the 50-day moving average falls below the 200-day moving average. 
For those betting on these miners to sparkle, the charts suggest the treasure hunt may be on pause.
<h2 class="wp-block-heading">Barrick Gold Stock: Treading Below The Glitter Line</h2>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="812" height="556" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27094639/GOLD-Death-Cross.jpg" alt="" class="wp-image-709375" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27094639/GOLD-Death-Cross.jpg 812w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27094639/GOLD-Death-Cross-300x205.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27094639/GOLD-Death-Cross-768x526.jpg 768w" sizes="(max-width: 812px) 100vw, 812px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Barrick Gold&#8217;s stock is down 11.97% year-to-date, with its recent performance offering little reason to cheer. The stock sits at $15.65, below its 20-day ($16.53) and 50-day ($17.86) simple moving averages.
While its relative strength index at 34.24 suggests it's approaching oversold territory, the MACD indicator, at a negative 0.61 confirms the bearish sentiment.
Adding a flicker of hope, GOLD&#8217;s eight-day SMA ($15.64) provides a faint bullish signal as the stock barely clings to this short-term moving average. 
But let's not get ahead of ourselves—geopolitical tensions and rising U.S. Treasury yields continue to cast a shadow over gold prices.
Read Also: <a href="https://www.benzinga.com/24/12/42409098/newmont-lays-off-senior-employees-pursuing-further-cost-controls">Newmont Lays Off Senior Employees Pursuing More Cost Controls</a>
<h2 class="wp-block-heading">Newmont Corp Stock: Gold's Gloomy Cousin</h2>
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="805" height="551" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27094651/NEM-Death-Cross.jpg" alt="" class="wp-image-709376" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27094651/NEM-Death-Cross.jpg 805w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27094651/NEM-Death-Cross-300x205.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27094651/NEM-Death-Cross-768x526.jpg 768w" sizes="(max-width: 805px) 100vw, 805px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Newmont, down 6.89% year-to-date, isn't faring any better. Its share price of $38.09 sits below its 20-day ($40.24), 50-day ($44.27), and 200-day ($44.86) SMAs—a trifecta of bearish indicators. 
The MACD reading of a negative 1.65 and an RSI of 32.28 suggest further downside is likely, with selling pressure mounting.
Even safe-haven demand for gold amid geopolitical tensions hasn't managed to prop up these miners. Rising U.S. dollar strength and Treasury yields have dampened gold's appeal, turning a potential golden opportunity into fool's gold for investors.
<h2 class="wp-block-heading">Outlook: Mining For Better Days?</h2>
With gold prices stuck between geopolitical jitters and the gravitational pull of stronger U.S. economic data, Barrick and Newmont's Death Cross signals are a clear warning for investors. 
Until the macroeconomic winds shift or gold prices break resistance, these mining heavyweights may find themselves digging deeper into bearish territory.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/12/42672565/why-trumps-return-to-office-could-drive-gold-demand-in-2025">Why Trump&#8217;s Return To Office Could Drive Gold Demand In 2025</a></li>
</ul>
Photo: Shutterstock

Technicals

Commodities

Signals

Gold Mining Leaders Barrick, Newmont Sink Deeper As Death Cross Looms

WIIM

BITF

COIN

HIVE

MARA

MSTR

RIOT

Shares of Bitcoin miners and crypto-linked stocks are trading lower amid a drop in Bitcoin.

EQT's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) short percent of float has fallen 6.68% since its last report. The company recently reported that it has 19.33 million shares sold short, which is 3.91% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.82 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>EQT Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735316122_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for EQT has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing EQT's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, EQT's peer group average for short interest as a percentage of float is 7.53%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About EQT?

Old Republic Intl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORI#NYSE">ORI</a>) short percent of float has fallen 8.15% since its last report. The company recently reported that it has 2.72 million shares sold short, which is 1.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Old Republic Intl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735316117_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Old Republic Intl has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Old Republic Intl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Old Republic Intl's peer group average for short interest as a percentage of float is 2.02%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About Old Republic Intl?

ServiceNow's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) short percent of float has risen 12.18% since its last report. The company recently reported that it has 3.60 million shares sold short, which is 1.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.88 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>ServiceNow Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735316113_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for ServiceNow has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing ServiceNow's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, ServiceNow's peer group average for short interest as a percentage of float is 4.99%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About ServiceNow?

ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) has outperformed the market over the past 10 years by 9.65% on an annualized basis producing an average annual return of 20.85%. Currently, ASML Holding has a market capitalization of $280.80 billion. 
Buying $1000 In ASML: If an investor had bought $1000 of ASML stock 10 years ago, it would be worth $6,619.06 today based on a price of $713.73 for ASML at the time of writing.
<h3>ASML Holding's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735316108_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASML

Here's How Much $1000 Invested In ASML Holding 10 Years Ago Would Be Worth Today

Rail Vision Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVSN#NASDAQ">RVSN</a>) saw its shares rise on Friday after announcing a <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42700675/rail-vision-receives-israel-railways-regulation-approval-for-its-mainline-products" rel="noreferrer noopener">major achievement in railway safety. </a>The company revealed it had received certification approval for the installation of its MainLine Systems on Israel Railways&#8217; passenger locomotives.
This milestone triggers a $300,000 milestone payment and positions Rail Vision for potential future volume procurement from Israel Railways.
CEO Shahar Hania emphasized that the certification demonstrates Rail Vision&#8217;s commitment to excellence and compliance with industry standards.
&#8220;We have met the strict certification standard, which aims to enable Israel Railways&#8217; future plans of high-volume procurement of Rail Vision products and services,&#8221; Hania added.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/small-cap/24/12/42700917/3-russell-2000-tech-stocks-skyrocketed-1000-more-2024-analysts-getting-started" rel="noreferrer noopener">3 Russell 2000 Tech Stocks That Skyrocketed 1,000% Or More In 2024: Analysts Say They&#8217;re Just Getting Started</a>
The company&#8217;s MainLine system is designed to enhance driver awareness with advanced obstacle detection and classification technology.
Tailored for main line operations, the system provides real-time, actionable data to operators, mitigating risks, preventing collisions, and ensuring smooth operations on busy rail networks.
This achievement solidifies Rail Vision&#8217;s position in the railway safety technology market, with further growth potential in the future.
Recently, the company announced its participation in MxV Rail&#8217;s Technology Roadmap Program, a leading initiative focused on establishing minimum interoperable standards and advancing systems to enhance rail safety<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42668514/rail-vision-to-join-mxv-rails-technology-roadmap-program-to-improve-safety-and-efficiency-of-rail-" rel="noreferrer noopener"> and efficiency across North America.</a>
Through its involvement in the program, Rail Vision will help shape the development of interoperable standards, establishing itself as a key contributor to the evolution of rail technology in the U.S.
Price Action: RVSN shares are trading higher by 34.4% to $1.04&nbsp;at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/12/42638753/quantum-computing-the-new-ai-a-look-at-the-rapidly-expanding-market-and-top-stocks-for-2025" target="_blank" rel="noreferrer noopener">Quantum Computing: The New AI? A Look at the Rapidly Expanding Market and Top Stocks For 2025</a></li>
</ul>

Equities

Movers

RVSN

What's Going On With Rail Vision Stock On Friday?

Amedisys Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMED#NASDAQ">AMED</a>) shares are trading higher on Friday after the company announced it extended its <a target="_blank" href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0000896262/048b8c3e-592e-42de-a13b-289ffd8da57d.pdf" rel="noreferrer noopener">merger</a> deadline with UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>).
In an exchange filing, the companies entered into a waiver agreement, further advancing their merger deal, originally<a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41987383/unitedhealths-optum-defends-multi-billion-dollar-amedisys-deal-ensures-competitive-landscape" rel="noreferrer noopener"> announced on June 26, 2023.</a>
Under the terms of the agreement, Merger Sub, a wholly owned subsidiary of UnitedHealth, will merge with Amedisys, with Amedisys continuing to operate as a subsidiary of UnitedHealth Group.
The companies have agreed to push their $3.3 billion merger deadline to next year. This extension follows intense scrutiny from the U.S. Department of Justice, Reuters reports.
Over a month ago, the DOJ and three U.S. states <a target="_blank" href="https://www.benzinga.com/news/legal/24/11/41917050/justice-department-moves-to-block-unitedhealths-amedisys-takeover-whats-going-on" rel="noreferrer noopener">filed a lawsuit to prevent the deal.</a> They argued that the merger would harm competition in the home health services market.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42703460/amedisys-rigetti-computing-and-other-big-stocks-moving-higher-on-friday" rel="noreferrer noopener">Amedisys, Rigetti Computing And Other Big Stocks Moving Higher On Friday</a>
The waiver allows both Amedisys and UnitedHealth Group to extend the period during which they cannot terminate the merger due to delays.
The companies have agreed to waive their right to terminate the agreement until the earlier of two conditions: 5:00 p.m. New York time on the tenth business day after a final order from the U.S. District Court for the District of Maryland permanently blocking the merger, or 11:59 p.m. on December 31, 2025.
The waiver ensures that the merger process remains in effect until one of these deadlines is reached.
The waiver also includes important financial and operational adjustments. The Regulatory Break Fee under the merger agreement is set at $275 million, which could increase to $325 million if certain divestiture milestones are not met.
Additionally, the waiver modifies certain operational restrictions and closing conditions, particularly those related to government approvals, and increases the revenue-related aspect of the "Burdensome Condition" definition.
Despite regulatory scrutiny and potential challenges, this waiver marks a key development in the ongoing efforts to finalize the merger.
The companies continue to work toward completing the deal, which is expected to provide both parties substantial synergies and growth opportunities.
Price Action: UNH shares are trading lower by 0.52% to $508.47 at last check Friday. AMED is up 4.48%.
Now Read This:
<ul>
<li><a href="https://www.benzinga.com/24/12/42699617/top-3-tech-and-telecom-stocks-that-may-rocket-higher-in-q4" target="_blank" rel="noreferrer noopener">Top 3 Tech And Telecom Stocks That May Rocket Higher In Q4</a></li>
</ul>

Health Care

AMED

Amedisys and UnitedHealth Extend Merger Deadline - What's Going On?

NVDA

NVIDIA shares are trading lower amid a broader tech selloff.

As Kentucky prepares to roll out its medical cannabis program on Jan. 1, 2025, the already complex issue of gun sales and weed will likely get even more complex due to federal regulations that prohibit marijuana <a href="https://www.benzinga.com/topic/guns">consumers from possessing firearms</a>.
Under federal law, as long as cannabis is classified as a Schedule I drug under the <a href="https://www.benzinga.com/topic/controlled-substances-act">Controlled Substances Act</a> (CSA) these complexities involving the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) will persist.
As of New Year&#8217;s Day, <a href="https://www.benzinga.com/24/11/42203777/kentucky-awards-first-medical-cannabis-dispensary-licenses">medical marijuana will be legal </a>in Kentucky although, due to the CSA, it remains <a href="https://www.benzinga.com/markets/cannabis/24/09/40859406/cannabis-prices-would-be-significantly-lower-in-the-us-if-legalized-study-finds">illegal under federal law</a>. Hence, Kentuckians who own or want to own guns are in a difficult position — a situation faced by gun owners across the U.S. who need or want to consume medical marijuana.
See Also: <a href="https://www.benzinga.com/news/legal/24/12/42694980/cannabis-use-among-teens-plummets-to-30-year-low-study-finds">Cannabis Use Among Teens Plummets To 30-Year Low, Study Finds</a>
<h2 class="wp-block-heading">ATF Paperwork Is Complicated</h2>
If you want to buy a gun, the process begins with ATF Form 4473. The form includes a question that specifically asks if the buyer is an unlawful user of, or addicted to, marijuana, among other controlled substances. Even if marijuana use is legal on a state level, answering yes to any part of that question can disqualify the individual from being able to buy a firearm. If you check yes, licensed sellers cannot legally sell you a gun.
&#8220;You cannot possess firearms and ammunition and also be a user of marijuana,&#8221; ATF Special Agent AJ Gibes said Wednesday, <a href="https://www.wdrb.com/news/starting-jan-1-kentuckians-will-have-to-choose-between-medical-marijuana-or-firearms/article_730a16b6-b80c-11ef-9721-93daace5ff86.html">reported</a> Kentucky's WDRB.com.
<h2 class="wp-block-heading">Give Up Your Right To Bear Arms</h2>
This not only applies to new gun purchases, current legal gun owners also face the tough decision of keeping their guns or partaking in the benefits of medical marijuana.
&#8220;If they wish to follow federal law and not be in violation of it, then they need to make the decision to divest themselves of those firearms,&#8221; Gibes said when asked if medical marijuana card owners are expected to give up their guns.
&#8220;We are not actively seeking and working solely on investigations involving just the possession of firearms and marijuana because of our finite resources,&#8221; he said. Still, for Kentuckians interested in following the law, this is the decision they'll face.
<h2 class="wp-block-heading">Don&#8217;t Lie To The ATF</h2>
Lying on form 4473 is punishable by up to 15 years in prison and/or up to a $250,000 fine. However, Gibes said charges are likely to only be pursued only in connection with another felony.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/small-cap/24/12/42700917/3-russell-2000-tech-stocks-skyrocketed-1000-more-2024-analysts-getting-started">3 Russell 2000 Tech Stocks That Skyrocketed 1,000% Or More In 2024: Analysts Say They&#8217;re Just Getting Started</a></li>
</ul>
Photo: Benzinga edit with images by&nbsp;<a href="https://unsplash.com/@sichpicsss?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash" target="_blank" rel="noreferrer noopener">Matthew Sichkaruk</a>&nbsp;on&nbsp;<a href="https://unsplash.com/photos/green-leaf-in-close-up-photography-eh3Sy2XQr7s?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash" target="_blank" rel="noreferrer noopener">Unsplash</a>&nbsp;and&nbsp;<a href="https://www.pexels.com/@pixabay/" target="_blank" rel="noreferrer noopener">Pixabay</a>&nbsp;on Pexels

Cannabis

Government

Legal

Guns And Cannabis Don't Mix In Kentucky: Medical Marijuana Law Takes Effect On New Year's Day

Investors with a lot of money to spend have taken a bullish stance on Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AXON, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 11 options trades for Axon Enterprise.
This isn't normal.
The overall sentiment of these big-money traders is split between 45% bullish and 45%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $27,820, and 10, calls, for a total amount of $415,370.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $150.0 to $790.0 for Axon Enterprise during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Axon Enterprise's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Axon Enterprise's whale trades within a strike price range from $150.0 to $790.0 in the last 30 days. 
<h3>Axon Enterprise Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735315243_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$30.0</td>
<td>$29.9</td>
<td>$30.0</td>
<td>$600.00</td>
<td>$72.0K</td>
<td align="right">252</td>
<td align="right">24</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$123.0</td>
<td>$121.0</td>
<td>$121.0</td>
<td>$500.00</td>
<td>$60.5K</td>
<td align="right">55</td>
<td align="right">5</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$467.7</td>
<td>$467.6</td>
<td>$467.6</td>
<td>$150.00</td>
<td>$46.7K</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$110.1</td>
<td>$110.0</td>
<td>$110.0</td>
<td>$500.00</td>
<td>$44.0K</td>
<td align="right">55</td>
<td align="right">10</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$215.0</td>
<td>$214.1</td>
<td>$215.0</td>
<td>$400.00</td>
<td>$43.0K</td>
<td align="right">213</td>
<td align="right">4</td>
</tr>
</tbody>
</table>

<h3>About Axon Enterprise</h3>
Axon Enterprise Inc develops, manufactures, and sells conducted energy devices and cloud-based digital evidence management software designed for use by law enforcement, corrections, military forces, private security personnel, and private individuals for personal defense. The company operates in two segments: Taser and software &amp; sensors. Taser develops and sells CEDs used for protecting users and virtual reality training. Software and sensors manufacture fully integrated hardware and cloud-based software solutions such as body cameras, automated license plate reading, and digital evidence management systems. Axon delivers its products worldwide and derives the majority of its revenue from the software &amp; sensors segment and geographically from the United States.
<h3>Present Market Standing of Axon Enterprise</h3>
<ul>
<li>With a volume of 82,242, the price of AXON is down -2.24% at $609.84. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 60 days.</li>
</ul>
<h3>What Analysts Are Saying About Axon Enterprise</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $750.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for Axon Enterprise, targeting a price of $800. 
&#x2A; In a positive move, an analyst from Morgan Stanley has upgraded their rating to Overweight and adjusted the price target to $700. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Axon Enterprise options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

AXON

Axon Enterprise's Options Frenzy: What You Need to Know

Investors with a lot of money to spend have taken a bearish stance on Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with LOW, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 14 options trades for Lowe's Companies.
This isn't normal.
The overall sentiment of these big-money traders is split between 35% bullish and 57%, bearish.
Out of all of the options we uncovered, 13 are puts, for a total amount of $807,820, and there was 1 call, for a total amount of $90,170.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $260.0 to $260.0 for Lowe's Companies over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Lowe's Companies stands at 632.0, with a total volume reaching 3,724.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Lowe's Companies, situated within the strike price corridor from $260.0 to $260.0, throughout the last 30 days.
<h3>Lowe's Companies Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735315237_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$16.15</td>
<td>$16.05</td>
<td>$16.15</td>
<td>$260.00</td>
<td>$101.7K</td>
<td align="right">486</td>
<td align="right">433</td>
</tr>
<tr>
<td>LOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$16.1</td>
<td>$15.9</td>
<td>$16.1</td>
<td>$260.00</td>
<td>$97.9K</td>
<td align="right">486</td>
<td align="right">554</td>
</tr>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$7.1</td>
<td>$7.05</td>
<td>$7.1</td>
<td>$260.00</td>
<td>$90.1K</td>
<td align="right">778</td>
<td align="right">127</td>
</tr>
<tr>
<td>LOW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$16.05</td>
<td>$15.15</td>
<td>$15.8</td>
<td>$260.00</td>
<td>$71.1K</td>
<td align="right">486</td>
<td align="right">167</td>
</tr>
<tr>
<td>LOW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$15.9</td>
<td>$15.5</td>
<td>$15.62</td>
<td>$260.00</td>
<td>$70.4K</td>
<td align="right">486</td>
<td align="right">212</td>
</tr>
</tbody>
</table>

<h3>About Lowe's Companies</h3>
Lowe's is the second-largest home improvement retailer in the world, operating more than 1,700 stores in the United States, after the 2023 divestiture of its Canadian locations (RONA, Lowe's Canada, Réno-Dépôt, and Dick's Lumber). The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's primarily targets retail do-it-yourself (around 70% of sales in 2024) and do-it-for-me customers, but has expanded its commercial and professional business clients to 30% from less than 20% in the past six years. We estimate Lowe's captures a high-single-digit share of the domestic home improvement market, based on US Census data and management's market size estimates.
After a thorough review of the options trading surrounding Lowe's Companies, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Lowe's Companies Standing Right Now?</h3>
<ul>
<li>With a trading volume of 213,256, the price of LOW is down by -0.07%, reaching $249.25.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 60 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Lowe's Companies</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $284.8.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Mizuho persists with their Outperform rating on Lowe's Companies, maintaining a target price of $305. 
&#x2A; An analyst from Wedbush downgraded its action to Neutral with a price target of $250. 
&#x2A; An analyst from RBC Capital persists with their Sector Perform rating on Lowe's Companies, maintaining a target price of $292. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on Lowe's Companies, maintaining a target price of $307. 
&#x2A; An analyst from Stifel persists with their Hold rating on Lowe's Companies, maintaining a target price of $270. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Lowe's Companies with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Lowe's Companies's Options: A Look at What the Big Money is Thinking

Shanghai AlphaGen Therapeutics and ArtBio forged a far-reaching agreement to expand ArtBio's market and develop new radioligand therapies. Additionally, Biocytogen Pharma signed an antibody evaluation/option agreement with Gilead Sciences.

Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership

Profit Setback For Simcere Pharma In Novel Drugs Quest

EpimAb Biotherapeutics sold global rights for a clinical-stage asset to Vignette Bio, a San Francisco startup, in a $635 million deal. Meanwhile, Shenzhen TargetRx raised $20 million by selling China commercial rights for an ALK inhibitor to Simcere.

Week In Review: EpimAb Sells T-Cell Engager In $635 Million Deal

Week In Review: EpimAb Sells T-Cell Engager In $635m Deal

CNTB

GILD

IVBXF

JBPHF

LEGN

SFOSF

Simcere Pharmaceutical Gr

<h4>Key Takeaways:</h4>

<ul>
	<li>The drugs Xiannuoxin and Mindewei have been conditionally approved for marketing in China. Despite the positive news, Simcere Pharmaceutical&rsquo;s stock managed only a muted rise and shares in Junshi Biosciences fell for two straight days</li>
	<li>With the latest wave of the pandemic already abating, demand for Covid treatments may lag expectations</li>
</ul>

By Molly Wen

China is deploying more drugs in its battle against Covid, which is good news for patients. But as the pandemic subsides, the growing list of treatments spells trouble for makers of the life-saving medicines.

Returning from the Lunar New Year holiday, two pharmaceutical companies announced progress in bringing new Covid drugs to the market, but the news was greeted with little fanfare by the stock market.

Last Sunday,&nbsp;Simcere Pharmaceutical Group Ltd.&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SMHGF#OTC">SMHGF</a>) and&nbsp;Shanghai Junshi Biosciences Co. Ltd.&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SHJBF#OTC">SHJBF</a>) gained conditional approval from Chinese regulators to market their oral Covid treatments, both small-molecule drugs used to treat patients with mild to moderate symptoms.

The newly approved treatments join a growing arsenal of drugs on the Chinese market for fighting Covid, alongside&nbsp;Pfizer&rsquo;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Paxlovid,&nbsp;Merck&rsquo;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Molnupiravir and&nbsp;Genuine Biotech&rsquo;s&nbsp;Azvudine.

However, as drug options have multiplied, market enthusiasm for Covid-related pharma stocks appears to have cooled. In the two days after the drug approval, Simcere Pharmaceutical&rsquo;s shares rose a mere 1.3%. Meanwhile at Junshi Biosciences, the Covid drug progress was not enough to cheer up investors worried about the overall profit outlook. The stock price fell 5.5% and 3.7% in the days after the approval, after the company estimated a&nbsp;net loss&nbsp;for last year.

Infection numbers spiked across China after the government relaxed its zero-Covid policy in December. But the current wave looks to have peaked, with no major resurgence during the Lunar New Year holiday and no new strains detected, according to the Chinese Center for Disease Control and Prevention (CDC). As of Jan. 26, the official tally stood at 216,000 hospitalized cases of Covid including 26,000 severe cases.

But success in containing Covid means the market for drugs to treat the inflection could be less buoyant than previously expected. With demand moderating, can the latest two drugs manage to turn a profit?

Simcere Pharmaceutical was quick to get down to business. A day after marketing approval was granted, the Beijing Municipal Medical Insurance Bureau priced Simcere&rsquo;s Covid drug&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0129/2023012900073.pdf">Xiannuoxin</a>&nbsp;at 750 yuan ($112) per pack, compared with an ex-factory price between 705 and 720 yuan per pack after tax. The company said it was ready to ramp up production and would sell through offline and online channels. By contrast, Junshi Biosciences has yet to release any pricing, although it vowed to start mass production and delivery of its drug&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0130/2023013000033.pdf">Mindewei</a>&nbsp;(VV116) soon.

<h4>Drugs with different bio targets</h4>

The two drugs use different pathways to fight Covid, but both methods are well-established in the research community. Simcere&rsquo;s Xiannuoxin targets 3CLpro, an enzyme involved in virus replication. The treatment works in a similar way to Pfizer&rsquo;s Paxlovid by combining two drugs to tackle the injection. The first drug, Simnotrelvir, inhibits 3CLpro while the second component, Ritonavir, enhances the anti-viral effects by slowing down the metabolism of Simnotrelvir.&nbsp; The company produces its own Simnotrelvir, while&nbsp;Ascletis Pharma&nbsp;(1672.HK)supplies it with Ritonavir.

Simcere Pharmaceutical said clinical trials indicated that its drug speeded up recovery time, based on data from 1,208 adult Covid patients with mild to moderate symptoms. The patients given Xiannuoxin took 1.5 fewer days to be symptom-free than people in the placebo group. The 11 tracked symptoms included coughing, fever, headaches, diarrhea, muscle pain and full-body aches.&nbsp; After five days of treatment, the viral load of patients in the drug group fell 96% and their Covid tests turned negative 2.2 days ahead of those in the placebo group. But the data from the clinical trials of Xiannuoxin have not been published in any academic journal yet.

The drug produced by Junshi Biosciences uses a different mechanism to obstruct Covid cells, targeting the same RdRp enzyme as Merck&rsquo;s Molnupiravir and Genuine Biotech&rsquo;s Azvudine.

The new drug Mindewei is an RdRp inhibitor, like the Covid drug Remdesivir which was approved in the U.S. for treating severe Covid conditions through intravenous injection. But by contrast, Mindewei can be taken orally and its active ingredient is a wide-spectrum coronavirus inhibitor recognized as safe and effective by the academic community.

Last December, the authoritative global journal &ldquo;New England Journal of Medicine&rdquo; compared Junshi&rsquo;s Mindewei to Pfizer&rsquo;s Paxlovid, based on the outcome of phase-three clinical trials for the Chinese drug. It found that Mindewei was not inferior to Paxlovid in treating Covid patients with mild to moderate symptoms and high risk factors.

Junshi Biosciences said its phase-three clinical trials showed that the drug shortened patients&rsquo; recovery time from Covid. In the study of 1,277 patients with mild to moderate symptoms, those treated with the drug were symptom-free two days sooner than their peers in the placebo group. &nbsp;But detailed data have not been released in any academic journal.

<h4>Limited profit prospects</h4>

At the end of last year, China wrestled with a dire shortage of Covid oral drugs as infections mounted and severe cases surged. Paxlovid sold for 1,890 yuan per pack and was in extremely short supply to the point where its black-market price reached 50,000 yuan per pack. Paxlovid did not make it onto the&nbsp;list&nbsp;of&nbsp; nationally insured drugs in January, while the Chinese drug Azvudine made the cut and was priced at 11.58 yuan per pill (3mg), down 35% from its initial marketing price and costing around 350 yuan for each course of treatment.

Xiannuoxin&rsquo;s ex-factory price per course is about 720 yuan. The drug retails at a higher price than Azvudine but lower than Paxlovid and Molnupiravir. When considering the cost of ingredients, which make up about half the retail price, and the 502 million yuan in R&amp;D costs, the drug would have to sell 1.7 million courses to turn a profit.

And crucially, the Covid drugs market is set to become more crowded, just as the infection curve moderates.

Among companies rushing to get their products approved are Guangdong Raynovent Biotech, &nbsp;a subsidiary of&nbsp;Guangdong Zhongsheng Pharmaceutical&nbsp;(002317.SZ),&nbsp;Kexing Bioproducts&nbsp;(688136.SH) and the Japanese company&nbsp;Shionogi &amp; Co., Ltd.. With more players boosting supply, profitability may well suffer.

In terms of valuation, Simcere Pharmaceutical has a price-to-sales (P/S) ratio of 4.3 times, lower than the 11.8 times for Junshi Biosciences. And the ratios of Zhongsheng Pharmaceutical and Kexing Bioproducts are 7.5 times and 3.3 times respectively. That means Simcere Pharmaceutical is not enjoying any premium simply because it is moving more swiftly with commercialization. On the contrary, investors appear to have more faith in the bigger innovative drug company, Junshi Biosciences.

Comments

Simcere Pharmaceutical Gr

News

Latest news for Simcere Pharmaceutical Gr (OTC:SMHGF) Stock

Friday, February 03, 2023

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga